John Volpone

Mr. Volpone joined CTI BioPharma in 2014 to lead interactions with its strategic business partners and licensing activities.  In 2017 he was promoted to Vice President, Strategic Operations, and assumed responsibility for CTI BioPharma’s for strategy and interactions with health authorities as well as program leadership for the global strategy of the pacritinib and pixuvri development and commercialization projects.

Mr. Volpone was the Program Lead, West Coast Search and Evaluation, for Bristol-Myers Squibb from 2010-2014, where he coordinated evaluation, diligence and negotiations for interactions with potential licensees across all therapeutic areas for opportunities originating on the west coast.  From 2004-2010 Mr. Volpone was the Director of Business Development and Alliance Management for ZymoGenetics, a publicly traded company which was acquired by BMS.  During this time he led multiple alliances with ZymoGenetics strategic partners, including Novo Nordisk and Merck Serono, and build and led the deal team that led to a $1 billion licensing deal, at the time the largest ever for a phase 1b asset, with BMS and the eventual acquisition of ZymoGenetics.  Mr. Volpone has a B.Sc. in biochemistry from the University of Washington and an MBA from Seattle University.